The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 273-284

  Clémenson, Céline ^a   Jouannot, Erwan ^b   Merino Trigo, Ana ^b   Rubin Carrez, Chantal ^b   Deutsch, Eric ^a,c  

^a Institut Gustave Roussy   (France)

^b SANOFI   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

AVE8062; Cetuximab; Cisplatin; Head and neck cancer; Irradiation; Vascular disrupting agent

Indexed keywords

CETUXIMAB; CISPLATIN; OMBRABULIN; PLATINUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CELL STRAIN FADU; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; SERINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879554909     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9852-4     Document Type: Article

References (49)

1. Fung C, Grandis JR (2010) Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 15:355-373
2. Marur S, Forastiere AA (2010) Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr Opin Oncol 22:206-211
3. Mehra R, Cohen RB, Burtness BA (2008) The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6:742-750
4. Pan Q, Gorin MA, Teknos TN (2009) Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opin Pharmacother 10:2291-2302
5. Bonner JA, Harari PM, Giralt J, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
6. Koutcher L, Sherman E, Fury M, et al. (2010) Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 81:915-922
7. Denekamp J, Hill SA, Hobson B (1983) Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19:271-275
8. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520-11539
9. Kanthou C, Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90:284-294
10. Siemann DW (2010) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37:63-74
11. Delmonte A, Sessa C (2009) AVE8062: A new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 18:1541-1548
12. Dark GG, Hill SA, Prise VE, et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834
13. Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604-1614
14. Hori K, Saito S, Sato Y, Kubota K (2001) Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 7:26-33
15. Nihei Y, Suzuki M, Okano A, et al. (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387-1395
16. Ohsumi K, Nakagawa R, Fukuda Y, et al. (1998) Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships. J Med Chem 41:3022-3032
17. Hori K, Saito S (2003) Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89:1334-1344
18. Hori K, Saito S, Nihei Y, et al. (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038
19. Lavisse S, Lejeune P, Rouffiac V, et al. (2008) Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 43:100-111
20. Sessa C, Soria JC, Tolcher A, et al. (2009) A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors. Ann Oncol 20: 7th International Symposium on Targeted Anticancer Therapies: abstract O36.
21. Kim TJ, Ravoori M, Landen CN, et al. (2007) Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67:9337-9345
22. Ohno T, Kawano K, Sasaki A, et al. (2002) Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int J Clin Oncol 7:171-176
23. Chaplin DJ, Hill SA (2002) The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54:1491-1496
24. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435
25. Plowman J, Dykes DJ, Hollingshead M, et al. (1999) Human Tumor Xenograft Models in NCI drug development. Feibig HH BA, editor. Basel: Karger. 101-125.
26. Maggiorella L, Frascogna V, Poullain MG, et al. (2001) The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis. Clin Cancer Res 7:2091-2095
27. Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7:730-742
28. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
29. McKeage MJ, Baguley BC (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116:1859-1871
30. Ekshyyan O, Rong Y, Rong X, et al. (2009) Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 8:2255-2265
31. Joschko MA, Webster LK, Bishop JF, et al. (1997) Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft. Cancer Chemother Pharmacol 40:534-539
32. Simons AL, Fath MA, Mattson DM, et al. (2007) Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18 F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 69:1222-1230
33. Morinaga Y, Suga Y, Ehara S, et al. (2003) Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94:200-204
34. Hori K, Furumoto S, Kubota K (2008) Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Cancer Sci 99:1485-1491
35. Ting LL, Belfi CA, Tefft M, Ngo FQ (1991) KHT sarcoma blood perfusion change after single-dose X-ray irradiation. Int J Radiat Biol 60:335-339
36. Siemann DW, Horsman MR (2004) Targeting the tumor vasculature: A strategy to improve radiation therapy. Expert Rev Anticancer Ther 4:321-327
37. Feng FY, Lopez CA, Normolle DP, et al. (2007) Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 13:2512-2518
38. Harari PM, Huang SM (2001) Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49:427-433
39. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940
40. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174
41. Krause M, Schutze C, Petersen C, et al. (2005) Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: A study on C225 in FaDu hSCC. Radiother Oncol 74:109-115
42. Goldman CK, Kim J, Wong WL, et al. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133
43. Chen DJ, Nirodi CS (2007) The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage. Clin Cancer Res 13:6555-6560
44. Dittmann K, Mayer C, Fehrenbacher B, et al. (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182-31189
45. Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157-161
46. Gorski DH, Beckett MA, Jaskowiak NT, et al. (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378
47. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191-1197
48. Raben D, Bianco C, Damiano V, et al. (2004) Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 3:977-983
49. Ng QS, Mandeville H, Goh V, et al. (2011) Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23:231-237